• 1
    Boily MC, Baggaley RF, Wang L, Masse B, White RG, Hayes RJ, et al.: Heterosexual risk of HIV-1 infection per sexual act: systematic review and meta-analysis of observational studies. Lancet Infect Dis 2009; 9:118129.
  • 2
    Lingappa JT, Hughes K, Baeten J, Fife K, De Bruyn G, Farquhar C, Kapiga S, Makhema J, Celum C, Partners in Prevention HSV/HIV Transmission Study Team: Infected Partner's Plasma HIV-1 RNA Level and the HIV-1 Set Point of Their Heterosexual Seroconverting Partners. In. 18th Conference on Retroviruses and Opportunistic Infections. Boston, MA, USA, 2011.
  • 3
    Pilcher CD, Tien HC, Eron JJ Jr, Vernazza PL, Leu SY, Stewart PW, et al.: Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:17851792.
  • 4
    Lingappa JR, Hughes JP, Wang RS, Baeten JM, Celum C, Gray GE, et al.: Estimating the impact of plasma HIV-1 RNA reductions on heterosexual HIV-1 transmission risk. PLoS ONE 2010; 5:e12598.
  • 5
    Baeten JM, Kahle E, Lingappa JR, Coombs RW, Delany-Moretlwe S, Nakku-Joloba E, et al.: Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med 2011; 3:77ra29.
  • 6
    Jenny C, Hooton TM, Bowers A, Copass MK, Krieger JN, Hillier SL, et al.: Sexually transmitted diseases in victims of rape. New Eng J Med 1990; 322:713716.
  • 7
    Sexton J, Garnett G, Rottingen JA: Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005; 32:351357.
  • 8
    Barnabas RV, Webb EL, Weiss HA, Wasserheit JN: The role of coinfections in HIV epidemic trajectory and positive prevention: a systematic review and meta-analysis. AIDS 2011; 25:15591573.
  • 9
    Slaughter L, Brown CR, Crowley S, Peck R: Patterns of genital injury in female sexual assault victims. Am J Obstet Gynecol 1997; 176:609616.
  • 10
    Adams JA, Girardin B, Faugno D: Signs of genital trauma in adolescent rape victims examined acutely. J Pediatr Adolesc Gynecol 2000; 13:88.
  • 11
    Haase AT: Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010; 464:217223.
  • 12
    Hiscott J, Kwon H, Genin P: Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Investig 2001; 107:143151.
  • 13
    Bouvet JP, Gresenguet G, Belec L: Vaginal pH neutralization by semen as a cofactor of HIV transmission. Clin Microbiol Infect 1997; 3:1923.
  • 14
    Munch J, Rucker E, Standker L, Adermann K, Goffinet C, Schindler M, et al.: Semen-derived amyloid fibrils drastically enhance HIV infection. Cell 2007; 131:10591071.
  • 15
    Roan NR, Muller JA, Liu H, Chu S, Arnold F, Sturzel CM, et al.: Peptides released by physiological cleavage of semen coagulum proteins form amyloids that enhance HIV infection. Cell Host Microbe 2011; 10:541550.
  • 16
    Sharkey DJ, Macpherson AM, Tremellen KP, Robertson SA: Seminal plasma differentially regulates inflammatory cytokine gene expression in human cervical and vaginal epithelial cells. Mol Hum Reprod 2007; 13:491501.
  • 17
    Lisco A, Munawwar A, Introini A, Vanpouille C, Saba E, Feng X, et al.: Semen of HIV-1-infected individuals: local shedding of herpesviruses and reprogrammed cytokine network. J Infect Dis 2012; 205:97105.
  • 18
    Berlier W, Cremel M, Hamzeh H, Levy R, Lucht F, Bourlet T, et al.: Seminal plasma promotes the attraction of Langerhans cells via the secretion of CCL20 by vaginal epithelial cells: involvement in the sexual transmission of HIV. Hum Reprod 2006; 21:11351142.
  • 19
    Sharkey DJ, Tremellen KP, Jasper MJ, Gemzell-Danielsson K, Robertson SA: Seminal fluid induces leukocyte recruitment and cytokine and chemokine mRNA expression in the human cervix after coitus. J Immunol 2012; 188:24452454.
  • 20
    Sharkey DJ, Macpherson AM, Tremellen KP, Mottershead DG, Gilchrist RB, Robertson SA: TGF-beta mediates proinflammatory seminal fluid signaling in human cervical epithelial cells. J Immunol 2012; 189:10241035.
  • 21
    Prakash M, Patterson S, Gotch F, Kapembwa MS: Recruitment of CD4 T lymphocytes and macrophages into the cervical epithelium of women after coitus. Am J Obstet Gynecol 2003; 188:376381.
  • 22
    Mavedzenge SN, Weiss HA, Montgomery ET, Blanchard K, De Bruyn G, Ramjee G, et al.: Determinants of differential HIV incidence among women in three southern African locations. J Acquir Immune Defic Syndr 2011; 58:8999.
  • 23
    Finkelhor D, Turner H, Ormrod R, Hamby SL: Violence, abuse, and crime exposure in a national sample of children and youth. Pediatrics 2009; 124:14111423.
  • 24
    Swartzendruber A, Brown JL, Sales JM, Murray CC, DiClemente RJ: Sexually transmitted infections, sexual risk behavior, and intimate partner violence among African American adolescent females with a male sex partner recently released from incarceration. J Adolesc Health 2012; 51:156163.
  • 25
    Diclemente RJ, Wingood GM, Crosby RA, Salazar LF, Head S, Rose E, et al.: Anal sex is a behavioural marker for laboratory-confirmed vaginal sexually transmissible infections and HIV-associated risk among African-American female adolescents. Sex Health 2009; 6:111116.
  • 26
    Geisler WM: Diagnosis and management of uncomplicated Chlamydia trachomatis infections in adolescents and adults: summary of evidence reviewed for the 2010 Centers for Disease Control and Prevention Sexually Transmitted Diseases Treatment Guidelines. Clin Infect Dis 2011; 53(Suppl 3):S92S98.
  • 27
    Workowski KA, Berman S: Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59:1110.
  • 28
    Prevention CfDCa. 2010 Sexually Transmitted Disease Surveillance. 2010 Available from: (accessed September 4 2010).
  • 29
    Hwang LY, Ma Y, Benningfield SM, Clayton L, Hanson EN, Jay J, et al.: Factors that influence the rate of epithelial maturation in the cervix in healthy young women. J Adolesc Health 2009; 44:103110.
  • 30
    Moss GB, Clemetson D, D'Costa L, Plummer FA, Ndinya-Achola JO, Reilly M, et al.: Association of cervical ectopy with heterosexual transmission of human immunodeficiency virus: results of a study of couples in Nairobi, Kenya. J Infect Dis 1991; 164:588591.
  • 31
    Mansfield MJ, Emans SJ: Adolescent menstrual irregularity. J Reprod Med 1984; 29:399410.
  • 32
    World Health Organization: World Health Organization multicenter study on menstrual and ovulatory patterns in adolescent girls. I. A multicenter cross-sectional study of menarche. World Health Organization Task Force on Adolescent Reproductive Health. J Adolesc Health 1986; 7:229235.
  • 33
    Hwang LY, Scott ME, Ma Y, Moscicki AB: Higher levels of cervicovaginal inflammatory and regulatory cytokines and chemokines in healthy young women with immature cervical epithelium. J Reprod Immunol 2011; 88:6671.
  • 34
    Madan RP, Carpenter C, Fiedler T, Kalyoussef S, McAndrew TC, Viswanathan S, et al.: Altered biomarkers of mucosal immunity and reduced vaginal lactobacillus concentrations in sexually active female adolescents. PLoS ONE 2012; 7:e40415.
  • 35
    Shrier LA, Bowman FP, Lin M, Crowley-Nowick PA: Mucosal immunity of the adolescent female genital tract. J Adolesc Health 2003; 32:183186.
  • 36
    Wang W, Owen SM, Rudolph DL, Cole AM, Hong T, Waring AJ, et al.: Activity of alpha- and theta-defensins against primary isolates of HIV-1. J Immunol 2004; 173:515520.
  • 37
    Hazrati E, Galen B, Lu W, Wang W, Ouyang Y, Keller MJ, et al.: Human alpha- and beta-defensins block multiple steps in herpes simplex virus infection. J Immunol 2006; 177:86588666.
  • 38
    Saidi H, Eslahpazir J, Carbonneil C, Carthagena L, Requena M, Nassreddine N, et al.: Differential modulation of human lactoferrin activity against both R5 and X4-HIV-1 adsorption on epithelial cells and dendritic cells by natural antibodies. J Immunol 2006; 177:55405549.
  • 39
    Valimaa H, Tenovuo J, Waris M, Hukkanen V: Human lactoferrin but not lysozyme neutralizes HSV-1 and inhibits HSV-1 replication and cell-to-cell spread. Virol J 2009; 6:53.
  • 40
    Lee-Huang S, Huang PL, Sun Y, Huang PL, Kung HF, Blithe DL, et al.: Lysozyme and RNases as anti-HIV components in beta-core preparations of human chorionic gonadotropin. Proc Natl Acad Sci USA 1999; 96:26782681.
  • 41
    Lee-Huang S, Maiorov V, Huang PL, Ng A, Lee HC, Chang YT, et al.: Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. Biochemistry 2005; 44:46484655.
  • 42
    John M, Keller MJ, Fam EH, Cheshenko N, Hogarty K, Kasowitz A, et al.: Cervicovaginal secretions contribute to innate resistance to herpes simplex virus infection. J Infect Dis 2005; 192:17311740.
  • 43
    Shust GF, Cho S, Kim M, Madan RP, Guzman EM, Pollack M, et al.: Female genital tract secretions inhibit herpes simplex virus infection: correlation with soluble mucosal immune mediators and impact of hormonal contraception. Am J Reprod Immunol 2010; 63:110119.
  • 44
    Keller MJ, Madan RP, Torres NM, Fazzari MJ, Cho S, Kalyoussef S, et al.: A randomized trial to assess anti-HIV activity in female genital tract secretions and soluble mucosal immunity following application of 1% tenofovir gel. PLoS ONE 2011; 6:e16475.
  • 45
    Ghartey JP, Carpenter C, Gialanella P, Rising C, McAndrew TC, Mhatre M, Tugetman J, Einstein MH, Chazotte C, Herold BC: Association of bactericidal activity of genital tract secretions with Escherichia coli colonization in pregnancy. Am J Obstet Gynecol 2012; 207:297.
  • 46
    Levinson P, Kaul R, Kimani J, Ngugi E, Moses S, MacDonald KS, et al.: Levels of innate immune factors in genital fluids: association of alpha defensins and LL-37 with genital infections and increased HIV acquisition. AIDS 2009; 23:309317.
  • 47
    Cole AM: Innate host defense of human vaginal and cervical mucosae. Curr Top Microbiol Immunol 2006; 306:199230.
  • 48
    Draper DL, Landers DV, Krohn MA, Hillier SL, Wiesenfeld HC, Heine RP: Levels of vaginal secretory leukocyte protease inhibitor are decreased in women with lower reproductive tract infections. Am J Obstet Gynecol 2000; 183:12431248.
  • 49
    McComb DE, Nichols RL, Semine DZ, Evrard JR, Alpert S, Crockett VA, et al.: Chlamydia trachomatis in women: antibody in cervical secretions as a possible indicator of genital infection. J Infect Dis 1979; 139:628633.
  • 50
    Tuffrey M, Alexander F, Taylor-Robinson D: Severity of salpingitis in mice after primary and repeated inoculation with a human strain of Chlamydia trachomatis. J Exp Pathol (Oxford) 1990; 71:403410.
  • 51
    Wolner-Hanssen P, Patton DL, Holmes KK: Protective immunity in pig-tailed macaques after cervical infection with Chlamydia trachomatis. Sex Transm Dis 1991; 18:2125.
  • 52
    Rank RG, Whittum-Hudson JA: Protective immunity to chlamydial genital infection: evidence from animal studies. J Infect Dis 2010; 201(Suppl 2):S168S177.
  • 53
    Batteiger BE, Tu W, Ofner S, Van Der Pol B, Stothard DR, Orr DP, et al.: Repeated Chlamydia trachomatis genital infections in adolescent women. J Infect Dis 2010; 201:4251.
  • 54
    Atashili J, Poole C, Ndumbe PM, Adimora AA, Smith JS: Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22:14931501.
  • 55
    Rebbapragada A, Howe K, Wachihi C, Pettengell C, Sunderji S, Huibner S, et al.: Bacterial vaginosis in HIV-infected women induces reversible alterations in the cervical immune environment. J Acquir Immune Defic Syndr 2008; 49:520522.
  • 56
    Gray RH, Li X, Kigozi G, Serwadda D, Brahmbhatt H, Wabwire-Mangen F, et al.: Increased risk of incident HIV during pregnancy in Rakai, Uganda: a prospective study. Lancet 2005; 366:11821188.
  • 57
    Anderson BL, Ghosh M, Raker C, Fahey J, Song Y, Rouse DJ, et al.: In vitro anti-HIV-1 activity in cervicovaginal secretions from pregnant and nonpregnant women. Am J Obstet Gynecol 2012; 207:65e61.
  • 58
    Valore EV, Wiley DJ, Ganz T: Reversible deficiency of antimicrobial polypeptides in bacterial vaginosis. Infect Immun 2006; 74:56935702.
  • 59
    Kalyoussef S, Nieves E, Dinerman E, Carpenter C, Viswanathan S, Oh J, Burd B, Angeletti RH, Buckheit KN, Fredricks DN, Madan RP, Keller MJ, Herold BC: Lactobacillus proteins are associated with the bactericidal activity against E. coli of female genital tract secretions. PLoS ONE. Accepted for publication
  • 60
    Dezzutti CS, Richardson BA, Marrazzo JM, Tugetman J, Ramjee G, Taha T, Chirenje ZM, Abdool Karim SS, Hillier SL, Herold BC, on behalf of the MTN Biomedical Sciences Working Group and the HPTN 035 Protocol Team: Mucosal E. coli bactericidal activity and immune mediators are associated with HIV-1 seroconversion in women participating in the HPTN 035 trial. J Infect Dis 2012; Oct 8 [Epub ahead of print].